Other antibodies against the same antigen:

Klon / Name:
M4
Aus Spezies:
Kaninchen
Mono-/polyklonal:
polyklonal (pAB) | anti-Gesamtprotein
Reinheit:
Serum
Menge (Masse):
n/a
Menge (Vol.):
100 µl
Preis (netto):
sold out, replaced by affinity purified antibody IG-731
Klon / Name:
IE273
Aus Spezies:
Maus
Mono-/polyklonal:
monoclonal (mAB)
Reinheit:
gereinigt an Protein A/G/...
Menge (Masse):
1.0 mg
Menge (Vol.):
500 µl
Preis (netto):
please enquire
Klon / Name:
IG-731
Aus Spezies:
Kaninchen
Mono-/polyklonal:
polyklonal (pAB) | anti-Gesamtprotein
Reinheit:
affinitätsgereinigt am Antigen
Menge (Masse):
25 µg
Menge (Vol.):
100 µl
Preis (netto):
295.00 €
Klon / Name:
Aus Spezies:
Kaninchen
Mono-/polyklonal:
polyklonal (pAB) | anti-Gesamtprotein
Reinheit:
Serum
Menge (Masse):
n/a
Menge (Vol.):
100 µl
Preis (netto):
155.00 €

 

Antibodies against related antigens:

There are no entries.

 

Artikel #:
0016-05
Antigen/Produkt:
VASP, vasodilator stimulated phosphoprotein
Synonym(e):
VASP
Uni-/SwissProt #:

P50552, B2RBT9, Q6PIZ1, Q93035

Klon / Name:
IE273
Aus Spezies:
Maus
Mono-/polyklonal:
monoclonal (mAB)
Isotyp:
IgG1
Reinheit:
gereinigt an Protein A/G/...
Menge (Masse):
50 µg
Menge (Vol.):
100 µl
Preis (netto):
195.00 €
Reaktion mit Spezies:
Mensch, Schwein, Rind
Anwendungen:
WB - Western Blot / Immunoblot, IF - Immunfluoreszenz, IHC - Immun-Histochemie, IP - Immunpräzipitation
Verdünnungen:
WB: 1:2,000 - 1:50,000; IF: 1:100 - 1:500; IP
Bemerkungen:

Der Antikörper erkennt sowohl die 46 kDa (Ser-157 Dephospho-) als auch die 50 kDa (Ser-157 Phospho-Form von VASP.

immunoGlobe VASP Antibodies in Basic and Clinical Research

Form:
steril filtrierte Lösung, mit Na-Azid, stabilisiert mit Träger(protein)
Immunisierung:
natürliches Protein
Epitop:
know (fine mapping)
Lagerung:
-20°C
Versand:
RT - ungekühlt
Verfügbarkeit:
vorrätig
Publikationen, die dieses Produkt verwenden:
1.
Mischnik, M. et al. A Boolean view separates platelet activatory and inhibitory signalling as verified by phosphorylation monitoring including threshold behaviour and integrin modulation. Mol Biosyst, in press (2013). (Article).
2.
Maruoka, M. et al. Abl-1-bridged tyrosine phosphorylation of VASP by Abelson kinase impairs association of VASP to focal adhesions and regulates leukaemic cell adhesion. Biochem. J. 441, 889–899 (2012). (Article).
3.
Glenn, J. R., White, A. E., Iyu, D. & Heptinstall, S. PGE(2) reverses G(s)-mediated inhibition of platelet aggregation by interaction with EP3 receptors, but adds to non-G(s)-mediated inhibition of platelet aggregation by interaction with EP4 receptors. Platelets 23, 344–351 (2012). (Article).
4.
Wangorsch, G. et al. Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation. BMC Syst Biol 5, 178 (2011). (Article).
5.
Tadokoro, S. et al. A potential role for α-actinin in inside-out αIIbβ3 signaling. Blood 117, 250–258 (2011). (Article).
6.
Peña, E., Padro, T., Molins, B., Vilahur, G. & Badimon, L. Proteomic signature of thrombin-activated platelets after in vivo nitric oxide-donor treatment: coordinated inhibition of signaling (phosphatidylinositol 3-kinase-γ, 14-3-3ζ, and growth factor receptor-bound protein 2) and cytoskeleton protein translocation. Arterioscler. Thromb. Vasc. Biol. 31, 2560–2569 (2011). (Article).
7.
Molins, B., Peña, E., de la Torre, R. & Badimon, L. Monomeric C-reactive protein is prothrombotic and dissociates from circulating pentameric C-reactive protein on adhered activated platelets under flow. Cardiovasc. Res. 92, 328–337 (2011). (Article).
8.
Iyú, D. et al. PGE1 and PGE2 modify platelet function through different prostanoid receptors. Prostaglandins Other Lipid Mediat. 94, 9–16 (2011). (Article).
9.
Iyú, D. et al. Mode of action of P2Y(12 ) antagonists as inhibitors of platelet function. Thromb. Haemost. 105, 96–106 (2011). (Article).
10.
Iyú, D., Glenn, J. R., White, A. E., Fox, S. C. & Heptinstall, S. Adenosine derived from ADP can contribute to inhibition of platelet aggregation in the presence of a P2Y12 antagonist. Arterioscler. Thromb. Vasc. Biol. 31, 416–422 (2011). (Article).
11.
Iyú, D. et al. P2Y₁₂ and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP. Platelets 22, 504–515 (2011). (Article).
12.
Aggarwal, S. et al. Attenuated vasodilatation in lambs with endogenous and exogenous activation of cGMP signaling: role of protein kinase G nitration. J. Cell. Physiol. 226, 3104–3113 (2011). (Article).
13.
Zhang, D. et al. Promotion of PDGF-induced endothelial cell migration by phosphorylated VASP depends on PKA anchoring via AKAP. Mol. Cell. Biochem. 335, 1–11 (2010). (Article).
14.
Wang, Y. et al. Icariin exterts negative effects on human gastric cancer cell invasion and migration by vasodilator-stimulated phosphoprotein via Rac1 pathway. Eur. J. Pharmacol. 635, 40–48 (2010). (Article).
15.
Iyú, D. et al. The role of prostanoid receptors in mediating the effects of PGE(2) on human platelet function. Platelets 21, 329–342 (2010). (Article).
16.
Geiger, J. et al. A protein phosphorylation-based assay for screening and monitoring of drugs modulating cyclic nucleotide pathways. Anal. Biochem. 407, 261–269 (2010). (Article).
17.
Zhang, Y. et al. Green tea (-)-epigallocatechin-3-gallate down-regulates VASP expression and inhibits breast cancer cell migration and invasion by attenuating Rac1 activity. Eur. J. Pharmacol. 606, 172–179 (2009). (Article).
18.
Mirone, V. et al. Platelet cyclic guanosine monophosphate as a biomarker of phosphodiesterase type 5 inhibitor efficacy in the treatment of erectile dysfunction: a randomized placebo-controlled study. Eur. Urol. 56, 1067–1073 (2009). (Article).
19.
Dugina, V., Zwaenepoel, I., Gabbiani, G., Clément, S. & Chaponnier, C. Beta and gamma-cytoplasmic actins display distinct distribution and functional diversity. J. Cell. Sci. 122, 2980–2988 (2009). (Article).
20.
Warnholtz, A. et al. A single loading dose of clopidogrel causes dose-dependent improvement of endothelial dysfunction in patients with stable coronary artery disease: results of a double-blind, randomized study. Atherosclerosis 196, 689–695 (2008). (Article).
21.
Birschmann, I. et al. Use of functional highly purified human platelets for the identification of new proteins of the IPP signaling pathway. Thromb. Res. 122, 59–68 (2008). (Article).
22.
Benz, P. M. et al. Cytoskeleton assembly at endothelial cell-cell contacts is regulated by alphaII-spectrin-VASP complexes. J. Cell Biol. 180, 205–219 (2008). (Article).
23.
Zhang, L. et al. Effect of matrine on HeLa cell adhesion and migration. Eur. J. Pharmacol. 563, 69–76 (2007). (Article).
24.
Blume, C. et al. AMP-activated protein kinase impairs endothelial actin cytoskeleton assembly by phosphorylating vasodilator-stimulated phosphoprotein. J. Biol. Chem. 282, 4601–4612 (2007). (Article).
25.
Van der Ven, P. F. M. et al. Unusual splicing events result in distinct Xin isoforms that associate differentially with filamin c and Mena/VASP. Exp. Cell Res. 312, 2154–2167 (2006). (Article).
26.
Galler, A. B. et al. VASP-dependent regulation of actin cytoskeleton rigidity, cell adhesion, and detachment. Histochem. Cell Biol. 125, 457–474 (2006). (Article).
27.
August, M. et al. Mechanisms underlying dysfunction of carotid arteries in genetically hyperlipidemic rabbits. Nitric Oxide 15, 241–251 (2006). (Article).
28.
Lohmann, S. M. & Walter, U. Tracking functions of cGMP-dependent protein kinases (cGK). Front. Biosci. 10, 1313–1328 (2005). (Article).
29.
Geiger, J. et al. Monitoring of clopidogrel action: comparison of methods. Clin. Chem. 51, 957–965 (2005). (Article).
30.
Dunkern, T. R. & Hatzelmann, A. The effect of Sildenafil on human platelet secretory function is controlled by a complex interplay between phosphodiesterases 2, 3 and 5. Cell. Signal. 17, 331–339 (2005). (Article).
31.
Gustavsson, A., Yuan, M. & Fällman, M. Temporal dissection of beta1-integrin signaling indicates a role for p130Cas-Crk in filopodia formation. J. Biol. Chem. 279, 22893–22901 (2004). (Article).
32.
Wei, L., Muller, S., Ouyang, J., Stoltz, J.-F. & Wang, X. Changes of vasodilator-stimulated phosphoprotein (VASP) and its phosphorylation in endothelial cells exposed to laminar flow. Clin. Hemorheol. Microcirc. 28, 113–120 (2003). (Article).
33.
Muller, S. et al. Expression and Location of VASP in human Endothelial Cells: Effect of a Laminar Shear Stress. J. Mech. Med. Biol. 3, 49 (2003). (Article).
34.
Mollnau, H. et al. Nebivolol prevents vascular NOS III uncoupling in experimental hyperlipidemia and inhibits NADPH oxidase activity in inflammatory cells. Arterioscler. Thromb. Vasc. Biol. 23, 615–621 (2003). (Article).
35.
Anderson, S. I., Behrendt, B., Machesky, L. M., Insall, R. H. & Nash, G. B. Linked regulation of motility and integrin function in activated migrating neutrophils revealed by interference in remodelling of the cytoskeleton. Cell Motil. Cytoskeleton 54, 135–146 (2003). (Article).
36.
Schulz, E. et al. Functional and biochemical analysis of endothelial (dys)function and NO/cGMP signaling in human blood vessels with and without nitroglycerin pretreatment. Circulation 105, 1170–1175 (2002). (Article).
37.
Mollnau, H. et al. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ. Res. 90, E58–65 (2002). (Article).
38.
Ibarra-Alvarado, C., Galle, J., Melichar, V. O., Mameghani, A. & Schmidt, H. H. H. W. Phosphorylation of blood vessel vasodilator-stimulated phosphoprotein at serine 239 as a functional biochemical marker of endothelial nitric oxide/cyclic GMP signaling. Mol. Pharmacol. 61, 312–319 (2002). (Article).
39.
Obergfell, A. et al. The molecular adapter SLP-76 relays signals from platelet integrin alphaIIbbeta3 to the actin cytoskeleton. J. Biol. Chem. 276, 5916–5923 (2001). (Article).
40.
Mülsch, A. et al. Effects of in vivo nitroglycerin treatment on activity and expression of the guanylyl cyclase and cGMP-dependent protein kinase and their downstream target vasodilator-stimulated phosphoprotein in aorta. Circulation 103, 2188–2194 (2001). (Article).
41.
Smolenski, A., Poller, W., Walter, U. & Lohmann, S. M. Regulation of human endothelial cell focal adhesion sites and migration by cGMP-dependent protein kinase I. J. Biol. Chem. 275, 25723–25732 (2000). (Article).
42.
Oelze, M. et al. Vasodilator-stimulated phosphoprotein serine 239 phosphorylation as a sensitive monitor of defective nitric oxide/cGMP signaling and endothelial dysfunction. Circ. Res. 87, 999–1005 (2000). (Article).
43.
Reinhard, M., Jarchau, T., Reinhard, K. & Walter, U. in Guidebook to the cytoskeleton and motor proteins 168–171 (Oxford University Press, 1999).
44.
Bachmann, C., Fischer, L., Walter, U. & Reinhard, M. The EVH2 domain of the vasodilator-stimulated phosphoprotein mediates tetramerization, F-actin binding, and actin bundle formation. J. Biol. Chem. 274, 23549–23557 (1999). (Article).
45.
Niebuhr, K. et al. A novel proline-rich motif present in ActA of Listeria monocytogenes and cytoskeletal proteins is the ligand for the EVH1 domain, a protein module present in the Ena/VASP family. EMBO J. 16, 5433–5444 (1997). (Article).
46.
Lambrechts, A. et al. The mammalian profilin isoforms display complementary affinities for PIP2 and proline-rich sequences. EMBO J. 16, 484–494 (1997). (Article).
47.
Abel, K., Lingnau, A., Niebuhr, K., Wehland, J. & Walter, U. Monoclonal antibodies against the focal adhesion protein VASP revealing epitopes involved in the interaction with two VASP binding proteins and VASP phosphorylation. European Journal of Cell Biology 69 (Suppl. 42), 39a (1996).
Include data sheet
1

Zurück

Bestellung oder Fragen zu diesem Produkt